Acknowledgments
The authors would like to thank Anneke Geurts-Moespot for performing the c-ELISA measurements, Thom Vlasveld and Bauke de Boer for providing background information on patient D and E, respectively, and Angel Ashikov and Katinka Redert for the valuable discussions on potential causes of the observed allelic imbalance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650–69.10.1373/clinchem.2009.140053Search in Google Scholar PubMed
2. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570–9.10.1373/clinchem.2010.149187Search in Google Scholar PubMed
3. Laarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM, et al. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One 2013;8:e75518.10.1371/journal.pone.0075518Search in Google Scholar PubMed PubMed Central
4. Biasiotto G, Belloli S, Ruggeri G, Zanella I, Gerardi G, Corrado M, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003;49:1981–8.10.1373/clinchem.2003.023440Search in Google Scholar PubMed
5. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004;103:2835–40.10.1182/blood-2003-10-3366Search in Google Scholar PubMed
6. Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241–7.10.1093/hmg/ddg225Search in Google Scholar PubMed
7. Peters HP, Laarakkers CM, Pickkers P, Masereeuw R, Boerman OC, Eek A, et al. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol 2013;14:70.10.1186/1471-2369-14-70Search in Google Scholar PubMed PubMed Central
8. Grebenchtchikov N, Geurts-Moespot AJ, Trentmann S, Andersen N, Bel Aiba RS, Allersdorfer A, et al. Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin. Clin Chem 2014;60:897–9.10.1373/clinchem.2014.221671Search in Google Scholar PubMed
9. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328–33.10.1182/blood-2005-05-2049Search in Google Scholar PubMed PubMed Central
10. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218–25.10.1182/blood-2011-02-337907Search in Google Scholar PubMed
Supplemental Material
The online version of this article (DOI: 10.1515/cclm-2015-0757) offers supplementary material, available to authorized users.
©2016 Walter de Gruyter GmbH, Berlin/Boston